Berlin based AI-company mediaire launches new product for quantitative MRI analysis

Berlin/Germany, 4 November 2019

mdbrain 2.0 will support radiologists in the diagnosis and follow up of neurological diseases like dementia or multiple sclerosis

When mdbrain 1.0 was launched in January 2019 as the first product of the young company mediaire, the strong focus was on supporting the diagnosis of dementia by quantifying brain volume (volumetry).
Based on customer feedback, new features were added to provide radiologists with a more powerful tool – mdbrain 2.0. It not only supports volumetric analysis of brain structures, but also allows the characterization of brain lesions for static and longitudinal studies. Such lesions are characteristic for diseases like Multiple Sclerosis and are important for diagnosis and follow up of patients living with this condition.
“We are very proud to now offer a robust tool for lesion characterization which also allows the assessment of lesion dynamics over time. While the radiologist is relieved from the time-consuming task of counting lesions, the neurologist can now make treatment decisions based on hard facts.” explains Dr Andreas Lemke, the CEO of mediaire.
Besides the new functionalities, mdbrain’s AI-algorithms have also been improved and their sample of healthy normal people has increased by several thousand.
“This allows us to calculate individual normal values for several brain regions comparable to lab reports. By accounting for age, sex & skull volume we can see within an age range of 18 and over 90 years whether a patient has an abnormal low brain volume corresponding to potential dementia.” describes Dr. Lemke further.
For interested professionals mediaire offers a free trial of its mdbrain software.

PRESS & MEDIA CONTACT

Herr Dr. Jens Opalka

mediaire GmbH
Möckernstrasse 63
10965 Berlin
Germany

Telefon: +49 30 2864 9067
Cell: +49 151 6161 2148
Email: j.opalka@mediaire.de

ABOUT mediaire

mediaire‘s mission is to improve the workflow of radiologists by more efficient quantitative image analysis.
Innovative software solutions powered by artificial intelligence (AI) enable us to analyse medical images in an increasing number of therapeutic areas and in a highly efficient way. As a consequence, the complex and demanding daily routine of Radiologists with increasing workload will be supported and facilitated - to the benefit of their patients who experience an improved quality & speed of diagnostic and therapeutic procedures.
With a fair pricing model we also want to ensure that our customers do not have to make a trade-off between quality and costs.
mediaire was founded in 2018 in Berlin by Dr. Andreas Lemke and Dr. Jörg Döpfert – both physicists with a background in MRI physics. Besides their scientific work in that area, both also gained broad experience in programming AI-powered software solutions in different businesses, including automotive and public transport. Since founding HQ-imaging in 2015, Andreas in particular has committed himself to MRI- quality assurance as well as to sequence and workflow optimization. Moreover, he gained deep experience in authorization procedures of medical products in his last position at Bosch.
The real founding history however, dates back to 2009 when the scientific paths of Andreas and Jörg crossed several times with the renowned radiologist Prof. Henrik Michaely. Coming from different backgrounds and discovering that each had the same goal, the idea of a scientifically and economically successful high-tech product took shape – a software powered by artificial intelligence (AI) that allows a highly efficient analysis of medical imaging data in Radiology to support radiologists in their daily routine.
Despite its relatively short business life mediaire has already won a number of highly regarded competitions, including the GoogleCloud StartUp Pitch, the Science4Life Venture Cup, the Deep Tech Award and the German national competition „digital innovation “.
On 21 January 2019 mediaire was officially certified as the provider of medical products as per DIN EN ISO 13485:2016 which enables its product mdbrain to be commercialized in Europe with a CE mark.

This release was published on openPR.